COGT

Cogent Biosciences, Inc. [COGT] Stock Forecast

Q: What is Cogent Biosciences, Inc. stock symbol ?

Cogent Biosciences, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol COGT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

COGT Stock Summary

The Moving Average Convergence Divergence (MACD) for COGT recently turned positive (within last 10 days).

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 71.2%

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

COGT has less than 1 year of cash runway

Top 10 Correlated Stocks

COGT

In the News

11:23 10 Dec 2023 COGT

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

08:00 10 Dec 2023 COGT

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

WALTHAM, Mass. and BOULDER, Colo.

08:00 10 Dec 2023 COGT

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

10:55 10 Dec 2023 COGT

These Are the Top 10 Holdings of David Kim

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

02:17 10 Dec 2023 COGT

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found in patients with advanced and/or treatment-resistant GIST.

07:02 10 Dec 2023 COGT

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.

08:00 10 Dec 2023 COGT

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.

01:16 10 Dec 2023 COGT

Cogent Biosciences: What's Ahead

Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs.

11:35 10 Dec 2023 COGT

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

12:02 10 Dec 2023 COGT

Cogent (COGT) Surges on Robust Data from Mastocytosis Study

Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.

COGT Financial details

Company Rating

Neutral

Market Cap

744.11M

Income

-168.89M

Revenue

Book val./share

3.52

Cash/share

3.24

Dividend

Dividend %

Employees

138

Optionable

Shortable

Yes

Earnings

02 Nov 2023

P/E

-4.41

Forward P/E

-4.19

PEG

-1.27

P/S

P/B

2.46

P/C

2.67

P/FCF

-7.07

Quick Ratio

8.04

Current Ratio

9.01

Debt / Equity

0.06

LT Debt / Equity

0.06

EPS (TTM)

-2.21

EPS next Y

-2.06

EPS next Q

-0.56

EPS this Y

37.8%

EPS next Y

-6.79%

EPS next 5Y

-10.67%

EPS last 5Y

-16.45%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

8.47%

SMA20

1.51%

SMA50

-19.1%

SMA100

-34.97%

Inst Own

76.38%

Inst Trans

0.61%

ROA

-48%

ROE

-60%

ROC

-0.6%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

86.12M

Shs Float

69.02M

Target Price

20.33

52W Range

6.43-15.68

52W High

-42.4%

52W Low

+44%

RSI

58.95

Rel Volume

1.51

Avg Volume

952.71K

Volume

1.43M

Perf Week

15.97%

Perf Month

-1.93%

Perf Quarter

-29.53%

Perf Half Y

-26.15%

Beta

-0.201

Volatility

0.36%, 0.69%

Prev Close

-1.48%

Price

8.64

Change

-0.23%

COGT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.56	2.95	0.71	0	0
Net income per share	-5.55	-3.97	-6	-1.64	-2.26
Operating cash flow per share	-5.22	-5.45	-3.24	-1.34	-2.02
Free cash flow per share	-5.31	-5.45	-3.24	-1.38	-2.14
Cash per share	12.63	4.91	21.86	5.01	4.41
Book value per share	9.68	4.17	21.18	4.89	4.35
Tangible book value per share	9.68	4.17	21.18	4.89	4.35
Share holders equity per share	9.68	4.17	21.18	4.89	4.35
Interest debt per share	0.61	0.79	0.47	0.07	0.4
Market cap	109.54M	21.95M	124.44M	375.85M	679.03M
Enterprise value	53.87M	-9.45M	-112.54M	159.33M	558.79M
P/E ratio	-3.17	-0.72	-1.87	-5.23	-5.12
Price to sales ratio	11.25	0.98	15.81	0	0
POCF ratio	-3.37	-0.53	-3.47	-6.4	-5.72
PFCF ratio	-3.32	-0.53	-3.47	-6.21	-5.41
P/B Ratio	1.82	0.69	0.53	1.75	2.66
PTB ratio	1.82	0.69	0.53	1.75	2.66
EV to sales	5.53	-0.42	-14.3	0	0
Enterprise value over EBITDA	-1.55	0.29	1.25	-2.11	-3.78
EV to operating cash flow	-1.66	0.23	3.14	-2.71	-4.71
EV to free cash flow	-1.63	0.23	3.14	-2.63	-4.45
Earnings yield	-0.32	-1.38	-0.53	-0.19	-0.2
Free cash flow yield	-0.3	-1.89	-0.29	-0.16	-0.18
Debt to equity	0.06	0.19	0.02	0.01	0.08
Debt to assets	0.04	0.12	0.02	0.01	0.07
Net debt to EBITDA	1.61	0.98	2.64	2.87	0.81
Current ratio	3.25	3.06	18.7	13.04	9.87
Interest coverage	0	0	0	0	-37.06
Income quality	0.94	1.3	0.48	0.81	0.85
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.77	0.49	2.21	0	0
Research and developement to revenue	3.93	1.94	9.23	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0	0	0.03	0.06
Capex to revenue	-0.06	0	0	0	0
Capex to depreciation	-0.42	-0.03	0	-11.69	-1.17
Stock based compensation to revenue	0.32	0.14	0.76	0	0
Graham number	34.76	19.3	53.45	13.43	14.87
ROIC	-0.59	-0.7	-0.3	-0.34	-0.47
Return on tangible assets	-0.4	-0.61	-0.26	-0.31	-0.44
Graham Net	8.7	2.79	20.39	4.61	3.65
Working capital	56.06M	27.34M	231.82M	205.56M	238.12M
Tangible asset value	60.23M	31.76M	234.67M	214.18M	255.74M
Net current asset value	55.31M	22.93M	228.66M	204.73M	219.89M
Invested capital	0.06	0.19	0.02	0.01	0.08
Average receivables	1.25M	1.83M	1000K	0	0
Average payables	1.43M	2.35M	1.96M	2.11M	4.66M
Average inventory	37.5K	0	0	0	0
Days sales outstanding	62.55	32.45	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	5.84	11.25	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.57	-0.95	-0.28	-0.34	-0.52
Capex per share	-0.09	0	0	-0.04	-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.48	-0.5	-0.48	-0.59	-0.64
Operating cash flow per share	-0.49	-0.42	-0.56	-0.43	0
Free cash flow per share	-0.54	-0.45	-0.57	-0.45	0
Cash per share	4.16	3.68	3.11	4.41	3.24
Book value per share	4.17	3.63	3.16	4.66	3.52
Tangible book value per share	4.17	3.63	3.16	4.66	3.52
Share holders equity per share	4.17	3.63	3.16	4.66	3.52
Interest debt per share	0.31	0.31	0.21	0.26	0.22
Market cap	1.04B	814.86M	763.23M	885.08M	840.12M
Enterprise value	917.59M	694.62M	621.99M	690.12M	772.48M
P/E ratio	-7.79	-5.74	-5.62	-5.02	-3.79
Price to sales ratio	0	0	0	0	0
POCF ratio	-30.14	-27.71	-19.31	-27.6	0
PFCF ratio	-27.5	-25.97	-18.79	-26.56	0
P/B Ratio	3.58	3.19	3.41	2.54	2.77
PTB ratio	3.58	3.19	3.41	2.54	2.77
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-27.71	-15.88	-14.63	-14.66	-12.97
EV to operating cash flow	-26.64	-23.62	-15.74	-21.52	0
EV to free cash flow	-24.31	-22.14	-15.31	-20.71	0
Earnings yield	-0.03	-0.04	-0.04	-0.05	-0.07
Free cash flow yield	-0.04	-0.04	-0.05	-0.04	0
Debt to equity	0.07	0.08	0.09	0.06	0.06
Debt to assets	0.06	0.07	0.07	0.05	0.05
Net debt to EBITDA	3.64	2.75	3.32	4.14	1.14
Current ratio	12.59	9.87	10.71	12.99	9.01
Interest coverage	-24.55	-20.73	9.3	0	0
Income quality	0.98	0.74	1.02	0.73	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.1	0.07	0.03	0.04	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.89	-2.1	-1.53	-1.03	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.7	6.41	5.84	7.86	7.13
ROIC	-0.11	-0.13	-0.14	-0.11	-0.17
Return on tangible assets	-0.1	-0.12	-0.13	-0.11	-0.16
Graham Net	3.56	3.04	2.55	3.82	2.63
Working capital	272.87M	238.12M	205.15M	308.76M	278.12M
Tangible asset value	289.94M	255.74M	223.56M	348.43M	302.9M
Net current asset value	254.8M	219.89M	186.64M	290.58M	260.29M
Invested capital	0.07	0.08	0.09	0.06	0.06
Average receivables	0	0	0	0	0
Average payables	3.79M	4.97M	5.01M	5.67M	8.51M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.11	-0.14	-0.15	-0.13	-0.18
Capex per share	-0.05	-0.03	-0.02	-0.02	0

COGT Frequently Asked Questions

What is Cogent Biosciences, Inc. stock symbol ?

Cogent Biosciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol COGT

Is Cogent Biosciences, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $20.33. The lowest prediction is $15 and the highest is $24

What is COGT stock prediction ?

What is Cogent Biosciences, Inc. stock quote today ?

Cogent Biosciences, Inc. stock price is $8.64 today.

Is Cogent Biosciences, Inc. stock public?

Yes, Cogent Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 952.71K
Market Capitalization 744.11M
Employee 138
CEO Mr. Andrew R. Robbins M.B.A.
Headquarters Cambridge,MA,US
IPO Date 2018-03-29
Website https://www.cogentbio.com

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.